BR112013015509A2 - composto ou sal do mesmo, composição farmacêutica, métodos para produzir efeito antiprogestacional em paciente e para tratar condição dependente de progesterona e usos de composto ou sal farmaceuticamente aceitável do mesmo e de composição - Google Patents

composto ou sal do mesmo, composição farmacêutica, métodos para produzir efeito antiprogestacional em paciente e para tratar condição dependente de progesterona e usos de composto ou sal farmaceuticamente aceitável do mesmo e de composição

Info

Publication number
BR112013015509A2
BR112013015509A2 BR112013015509A BR112013015509A BR112013015509A2 BR 112013015509 A2 BR112013015509 A2 BR 112013015509A2 BR 112013015509 A BR112013015509 A BR 112013015509A BR 112013015509 A BR112013015509 A BR 112013015509A BR 112013015509 A2 BR112013015509 A2 BR 112013015509A2
Authority
BR
Brazil
Prior art keywords
compound
salt
composition
patient
producing
Prior art date
Application number
BR112013015509A
Other languages
English (en)
Inventor
Joseph S Podolski
Ronald D Wiehle
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44343114&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013015509(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Priority claimed from PCT/US2011/050859 external-priority patent/WO2012087389A1/en
Publication of BR112013015509A2 publication Critical patent/BR112013015509A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/0077—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom
    • C07J41/0083—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 substituted in position 11-beta by a carbon atom, further substituted by a group comprising at least one further carbon atom substituted in position 11-beta by an optionally substituted phenyl group not further condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/0045—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa not substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/0005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21
    • C07J7/001—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group
    • C07J7/004—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa
    • C07J7/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms not substituted in position 21 substituted in position 20 by a keto group substituted in position 17 alfa substituted in position 16
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J7/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms
    • C07J7/008—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of two carbon atoms substituted in position 21

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112013015509A 2010-03-22 2011-09-08 composto ou sal do mesmo, composição farmacêutica, métodos para produzir efeito antiprogestacional em paciente e para tratar condição dependente de progesterona e usos de composto ou sal farmaceuticamente aceitável do mesmo e de composição BR112013015509A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31626310P 2010-03-22 2010-03-22
PCT/US2010/062068 WO2011119194A1 (en) 2010-03-22 2010-12-23 Compositions and methods for non-toxic delivery of antiprogestins
PCT/US2011/050859 WO2012087389A1 (en) 2010-12-23 2011-09-08 Novel 19-nor-steroids and their use for treating progesterone-dependent conditions

Publications (1)

Publication Number Publication Date
BR112013015509A2 true BR112013015509A2 (pt) 2016-09-13

Family

ID=44343114

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112012023281A BR112012023281A2 (pt) 2010-03-22 2010-12-23 composto ou sal do mesmo, composição farmacêutica, métodos para produzir efeito antiprogestacional em paciente e para tratar condição dependente de progesterona e usos de composto ou sal do mesmo farmaceuticamente aceitável do mesmo e de composição
BR112013015509A BR112013015509A2 (pt) 2010-03-22 2011-09-08 composto ou sal do mesmo, composição farmacêutica, métodos para produzir efeito antiprogestacional em paciente e para tratar condição dependente de progesterona e usos de composto ou sal farmaceuticamente aceitável do mesmo e de composição

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112012023281A BR112012023281A2 (pt) 2010-03-22 2010-12-23 composto ou sal do mesmo, composição farmacêutica, métodos para produzir efeito antiprogestacional em paciente e para tratar condição dependente de progesterona e usos de composto ou sal do mesmo farmaceuticamente aceitável do mesmo e de composição

Country Status (24)

Country Link
US (3) US20130018027A1 (pt)
EP (2) EP2550288A1 (pt)
JP (4) JP5894143B2 (pt)
KR (2) KR20130009990A (pt)
CN (3) CN107260745A (pt)
AR (1) AR080692A1 (pt)
AU (4) AU2010348967C1 (pt)
BR (2) BR112012023281A2 (pt)
CA (1) CA2793712A1 (pt)
CL (1) CL2012002544A1 (pt)
CO (1) CO6602170A2 (pt)
CR (1) CR20120514A (pt)
EA (1) EA023743B1 (pt)
EC (1) ECSP12012226A (pt)
IL (2) IL221820B (pt)
MX (1) MX2012010327A (pt)
MY (1) MY164622A (pt)
NI (2) NI201200142A (pt)
NZ (1) NZ602525A (pt)
SG (3) SG183924A1 (pt)
TW (1) TWI581797B (pt)
UA (1) UA110030C2 (pt)
WO (1) WO2011119194A1 (pt)
ZA (1) ZA201207688B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111840246A (zh) * 2014-05-05 2020-10-30 艾尔建制药国际有限公司 用于抗孕激素的阴道递送的制剂和方法
KR20170084086A (ko) * 2014-11-17 2017-07-19 아르노 테라퓨틱스 인코포레이티드 오나프리스톤 연장-방출 조성물 및 방법
EP3353148A4 (en) 2015-09-25 2019-04-24 Context Biopharma Inc. PROCESS FOR THE PRODUCTION OF ONAPRISTONE INTERMEDIATE PRODUCTS
KR20180113988A (ko) 2015-12-15 2018-10-17 컨텍스트 바이오파마 인코포레이티드 비정질 오나프리스톤 조성물 및 그 제조방법
JP2019506443A (ja) * 2016-02-24 2019-03-07 イースタン バージニア メディカル スクール 改良された持効性注射用デポ型ブタン酸レボノルゲストレル懸濁製剤
WO2018102369A1 (en) 2016-11-30 2018-06-07 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2377418A1 (fr) * 1977-01-13 1978-08-11 Roussel Uclaf Nouveaux derives steroides 4,9-dieniques 11b-substitues, leur procede de preparation et leur application comme medicaments
ZA8231B (en) 1981-01-09 1982-11-24 Roussel Uclaf New 11 -substituted steroid derivatives, their preparation, their use as medicaments, the compositions containing them and the new intermediates thus obtained
FR2521565B1 (fr) 1982-02-17 1985-07-05 Dior Sa Parfums Christian Melange pulverulent de constituants lipidiques et de constituants hydrophobes, procede pour le preparer, phases lamellaires lipidiques hydratees et procede de fabrication, compositions pharmaceutiques ou cosmetiques comportant des phases lamellaires lipidiques hydratees
FR2522328B1 (fr) * 1982-03-01 1986-02-14 Roussel Uclaf Nouveaux produits derives de la structure 3-ceto 4,9 19-nor steroides, leur procede de preparation et leur application comme medicaments
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
DE3461090D1 (en) 1983-02-18 1986-12-04 Schering Ag 11-beta-aryl-estradienes, process for their preparation and pharmaceutical compositions containing them
US4780461A (en) 1983-06-15 1988-10-25 Schering Aktiengesellschaft 13α-alkyl-gonanes, their production, and pharmaceutical preparations containing same
EP0501523B1 (en) 1983-11-14 1997-04-09 Columbia Laboratories, Inc. Bioadhesive compositions
DE3347126A1 (de) 1983-12-22 1985-07-11 Schering AG, 1000 Berlin und 4709 Bergkamen 11ss-aryl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3506785A1 (de) 1985-02-22 1986-08-28 Schering AG, Berlin und Bergkamen, 1000 Berlin 11ss-n,n-dimethylaminophenyl-estradiene, deren herstellung und diese enthaltende pharmazeutische praeparate
FR2598421B1 (fr) * 1986-05-06 1988-08-19 Roussel Uclaf Nouveaux produits 19-nor ou 19-nor d-homo steroides substitues en position 11b par un radical phenyle portant un radical alkynyle, leur procede de preparation, leur application comme medicaments et les compositions les renfermant
DE3625315A1 (de) 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
US5446178A (en) 1987-03-18 1995-08-29 Schering Aktiengesellschaft Process for preparing 19,11β-bridged steroids
DE3708942A1 (de) 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
EP0289073B1 (en) 1987-04-24 1991-11-27 Akzo N.V. Novel 11-aryloestrane and 11-arylpregnane derivatives
EP0321010B1 (en) 1987-12-12 1993-02-03 Akzo N.V. New 11-arylsteroid compounds
DE3820948A1 (de) 1988-06-16 1989-12-21 Schering Ag 10ss, 11ss-ueberbrueckte steroide
US4954490A (en) * 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
DE3822770A1 (de) 1988-07-01 1990-01-04 Schering Ag 13-alkyl-11ss-phenylgonane
US5077211A (en) 1988-07-06 1991-12-31 Applied Genetics, Inc. Purification and administration of dna repair enzymes
DE3832303A1 (de) 1988-09-20 1990-04-12 Schering Ag 11ss-phenyl-14ssh-steroide
DE3917274A1 (de) 1989-05-24 1990-11-29 Schering Ag 9(alpha)-hydroxy-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
DE3921059A1 (de) 1989-06-23 1991-01-10 Schering Ag 11(beta)-aryl-4-estrene, verfahren zu ihrer herstellung sowie deren verwendung als arzneimittel
DE4042007A1 (de) 1990-12-22 1992-06-25 Schering Ag 6,7-modifizierte-11(beta)-aryl-4-estrene
US5407928A (en) 1990-08-15 1995-04-18 Schering Aktiengesellschaft 11β-aryl-gona-4,9-dien-3-ones
DE4038128A1 (de) 1990-11-27 1992-06-04 Schering Ag 8-en-19, 11(beta)-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
JPH0735335B2 (ja) * 1991-02-28 1995-04-19 五十嵐 正雄 子宮内膜症の治療薬
ZA929315B (en) 1991-12-20 1993-05-24 Akzo Nv 17-spirofuran-3'-ylidene steroids.
DE4216004B4 (de) 1992-05-12 2008-03-27 Bayer Schering Pharma Akiengesellschaft Verwendung kompetitiver Progesteronantagonisten
DE4216003A1 (de) 1992-05-12 1993-11-18 Schering Ag Dissoziierte kompetitive Progesteronantagonisten
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
JPH07508987A (ja) 1992-07-01 1995-10-05 オーソ・フアーマシユーチカル・コーポレーシヨン １−アリールスルホニル，アリールカルボニルおよび１−アリールホスホニル−３−フェニル−１，４，５，６−テトラヒドロピリダジン
US5543150A (en) * 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
DE4332284C2 (de) 1993-09-20 1997-05-28 Jenapharm Gmbh 11-Benzaldoxim-17beta-methoxy-17alpha-methoxymethyl-estradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4332283A1 (de) 1993-09-20 1995-04-13 Jenapharm Gmbh Neue 11-Benzaldoximestradien-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE4434488A1 (de) 1994-09-14 1996-03-21 Schering Ag Steroidester und -amide, Verfahren zu ihrer Herstellung und ihre pharmazeutische Verwendung
US5576310A (en) 1994-09-20 1996-11-19 Jenapharm Gmbh 11-benzaldoxime-17β-methoxy-17α-methoxymethyl-estrasdiene derivatives, methods for their production and pharmaceuticals containing such compounds
US5688808A (en) 1994-12-22 1997-11-18 Ligand Pharmaceuticals Incorporated Steroid receptor modulator compounds and methods
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
US6861415B2 (en) 1996-05-01 2005-03-01 The United States Of America As Represented By The Department Of Health And Human Services 21-substituted progesterone derivatives as new antiprogestational agents
WO1998008471A1 (en) * 1996-08-30 1998-03-05 The Population Council, Inc. Vaginal application mifepristone
US5753655A (en) 1996-10-10 1998-05-19 Ortho Pharmaceutical Corporation 1-arylsulphonyl, arylcarbonyl and arylthiocarbonyl pyridazino derivatives and methods of preparation
DE19652408C2 (de) 1996-12-06 2002-04-18 Schering Ag Steroidester, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Arzneimitteln
US5993856A (en) * 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
DE19706061A1 (de) 1997-02-07 1998-08-13 Schering Ag Antigestagen wirksame Steroide mit fluorierter 17alpha-Alkylkette
US6197327B1 (en) * 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
DE19809845A1 (de) 1998-03-03 1999-09-09 Jenapharm Gmbh S-substituierte 11beta-Benzaldoxim-estra-4,9-dien-kohlensäurethiolester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende pharmazeutische Zubereitungen
US6172052B1 (en) * 1998-12-04 2001-01-09 Research Triangle Institute 17β-acyl-17α-propynyl-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6509334B1 (en) 1999-05-04 2003-01-21 American Home Products Corporation Cyclocarbamate derivatives as progesterone receptor modulators
US6417214B1 (en) 1999-05-04 2002-07-09 Wyeth 3,3-substituted indoline derivatives
US6306851B1 (en) 1999-05-04 2001-10-23 American Home Products Corporation Cyclocarbamate and cyclic amide derivatives
US6380235B1 (en) 1999-05-04 2002-04-30 American Home Products Corporation Benzimidazolones and analogues
US6391907B1 (en) 1999-05-04 2002-05-21 American Home Products Corporation Indoline derivatives
US6358948B1 (en) 1999-05-04 2002-03-19 American Home Products Corporation Quinazolinone and benzoxazine derivatives as progesterone receptor modulators
US6339098B1 (en) 1999-05-04 2002-01-15 American Home Products Corporation 2,1-benzisothiazoline 2,2-dioxides
US6369056B1 (en) 1999-05-04 2002-04-09 American Home Products Corporation Cyclic urea and cyclic amide derivatives
US6740645B1 (en) * 1999-09-03 2004-05-25 Research Triangle Institute 17β-acyl-17α-propynyl-11β-(cyclic amino) aryl steroids and their derivatives having antagonist hormonal properties
UA74168C2 (uk) * 1999-10-05 2005-11-15 Коламбіа Леборетеріс (Бермуда) Лімітед Лікування ендометріозу або безпліддя, або покращення плідності та застосування бета-адренергічного агоніста для виробництва лікарського засобу
US6476079B1 (en) * 1999-12-23 2002-11-05 Leiras Oy Devices for the delivery of drugs having antiprogestinic properties
SK287124B6 (sk) * 2000-10-18 2009-12-07 Schering Aktiengesellschaft Použitie antiprogestínu na prípravu liečiva
CN1210079C (zh) * 2001-04-25 2005-07-13 上海市计划生育科学研究所 阴道环制剂及其应用
EP1768625B1 (en) * 2004-07-09 2011-02-09 The Population Council, Inc. Sustained release compositions containing progesterone receptor modulators
CN1846703A (zh) * 2006-02-13 2006-10-18 程定超 米非司酮阴道给药制剂及其组成和制备方法
PT2148681E (pt) * 2007-04-20 2016-06-17 Preglem Sa Moduladores seletivos da progesterona no tratamento da hemorragia uterina
WO2009037704A1 (en) * 2007-09-20 2009-03-26 Bio-Pro Medical Ltd. Compositions and means for treating uterine leiomyomata, leiomyoma, myoma, uterine fibroids, endrometriosis, adenomyosis and related disorders by mifepristone
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids

Also Published As

Publication number Publication date
IL221820B (en) 2018-06-28
EP2550288A1 (en) 2013-01-30
CR20120514A (es) 2013-02-11
NZ602525A (en) 2014-01-31
US20130018027A1 (en) 2013-01-17
TWI581797B (zh) 2017-05-11
ZA201207688B (en) 2013-07-31
SG10201510568WA (en) 2016-01-28
KR102166867B1 (ko) 2020-10-19
MY164622A (en) 2018-01-30
KR20180104180A (ko) 2018-09-19
AU2016200575A1 (en) 2016-02-18
AU2017251837B2 (en) 2019-10-03
AU2016200575B2 (en) 2017-11-16
WO2011119194A1 (en) 2011-09-29
TW201200135A (en) 2012-01-01
EA201390959A1 (ru) 2013-11-29
AU2020200027A1 (en) 2020-01-30
UA110030C2 (uk) 2015-11-10
AU2017251837A1 (en) 2017-11-16
AU2010348967C1 (en) 2016-04-28
CN107260746A (zh) 2017-10-20
NI201200142A (es) 2013-04-12
BR112012023281A2 (pt) 2016-05-17
SG10201504913UA (en) 2015-07-30
CN102906103A (zh) 2013-01-30
JP2019123756A (ja) 2019-07-25
CO6602170A2 (es) 2013-01-18
JP2013522361A (ja) 2013-06-13
CA2793712A1 (en) 2011-09-29
MX2012010327A (es) 2012-11-16
AU2010348967A1 (en) 2012-09-27
US20150203526A1 (en) 2015-07-23
JP5894143B2 (ja) 2016-03-23
CN107260745A (zh) 2017-10-20
IL255679A (en) 2018-01-31
US20190127413A1 (en) 2019-05-02
KR20130009990A (ko) 2013-01-24
AU2010348967B2 (en) 2015-10-29
NI201300059A (es) 2014-06-06
JP2018016655A (ja) 2018-02-01
CL2012002544A1 (es) 2012-11-23
ECSP12012226A (es) 2012-11-30
EP3865502A1 (en) 2021-08-18
SG183924A1 (en) 2012-10-30
AR080692A1 (es) 2012-05-02
EA023743B1 (ru) 2016-07-29
JP2016029083A (ja) 2016-03-03

Similar Documents

Publication Publication Date Title
BR112015008365A2 (pt) composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente
BR112014014262A2 (pt) nanopartículas; composição farmacêutica; método de administrar um ou mais agentes terapêuticos, profiláticos, e/ou diagnósticos a um paciente em necessidade dos mesmos e método de preparação das partículas.
BR112015003332A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015003398A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015003376A8 (pt) composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e usos de quantidade eficiente de composto ou sal farmaceuticamente aceitável do mesmo ou composição farmacêutica
IL223783B (en) Compound 1-converted indole for use in the treatment of a disease or condition, a pharmaceutical preparation containing the compound and use of the compound to prepare a medicine
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
IL232308A (en) Compounds as modulators of atp-linked casting, pharmaceuticals containing them and their use in the preparation of drugs for the treatment of diseases and processes for their preparation
BR112015003397A2 (pt) composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
BRPI1007636A2 (pt) Composição farmacêutica, forma de dosagem, método para a preparação da composição farmacêutica, método de preparação da forma de dosagem e método de tratamento da dor
BR112015002858A2 (pt) composto, composição farmacêutica, uso de um composto, e, método para prevenir, controlar, tratar ou atenuar uma doença viral ou uma doença por hbv em um paciente
BR112013030045A2 (pt) composto da fórmula d-m-d ou um sal farmacêuticamente aceitável do mesmo; composto ou sal; composição farmacêutica; e método de tratamento de infecção por hepatite c em um paciente
BR112013011480A2 (pt) método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer
EP2726066A4 (en) DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME
BRPI1009860A2 (pt) composto, uso do mesmo, composição farmacêutica e método para tratamento terapêutico ou prevenção de doenças em humanos ou animais
HUE061596T2 (hu) Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben
BR112014010299A2 (pt) composição para prevenir e tratar doenças da cavidade oral; método de prevenção e tratamento de doenças da cavidade oral; e uso da composição
WO2013188847A8 (en) Compositions and methods for transmucosal absorption
ZA201209289B (en) Urea derivatives and their therapeutic use in the treatment of,inter alia,diseases of the respiratory tract
BR112013033078A2 (pt) partícula, composição farmacêutica, conjunto para o tratamento do câncer e método para o tratamento do câncer em um paciente
BR112013015509A2 (pt) composto ou sal do mesmo, composição farmacêutica, métodos para produzir efeito antiprogestacional em paciente e para tratar condição dependente de progesterona e usos de composto ou sal farmaceuticamente aceitável do mesmo e de composição
IL251543B (en) Use of gel compounds in the production of medicine to prevent or treat skin diseases
IL230957B (en) Pharmacy methods and preparations for the treatment of an eye disease in a patient
EP2497467A4 (en) PHARMACEUTICAL COMBINATIONS, PHARMACEUTICAL COMPOSITIONS, MEDICAMENT THEREFOR AND METHOD FOR TREATING ANIMALS
BRPI1009741A2 (pt) composição, método para prevenir ou tratar a mucosite em paciente mamífero, composição farmacêutica para adminstração tópica, e uso de uma composição

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2530 DE 02-07-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.